Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seres Therapeutics (MCRB) reported inducement equity grants made on September 4, 2026 under its 2022 Employment Inducement Award Plan to two new employees.

Rhea-AI Summary

Seres Therapeutics (MCRB) reported inducement equity grants made on September 4, 2026 under its 2022 Employment Inducement Award Plan to two new employees.

The Compensation and Talent Committee granted stock options to purchase an aggregate of 4,200 shares of Seres common stock, with an exercise price of $5.72 per share. The Inducement Plan is used exclusively for equity awards that serve as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and was adopted by the board in December 2022. Each option vests 25% on the first anniversary of the individual’s hire date, with the remaining 75% vesting in 6.25% increments after each three full months of continued service thereafter.

Key Figures

Inducement shares: 4,200 shares Exercise price: $5.72 per share Initial vesting: 25% +1 more

Inducement shares

4,200 shares

Stock options granted to two new employees on September 4, 2026

Exercise price

$5.72 per share

Stock options

Initial vesting

25%

Vests on the first anniversary of the employee's hire date

Subsequent vesting

6.25%

Vests after each three full months of service thereafter

Key Terms

live biotherapeutics, nasdaq listing rule 5635(c)(4)

2 terms

live biotherapeutics medical

"a leading live biotherapeutics company"

Live biotherapeutics are medicines that contain live microorganisms—such as bacteria or yeasts—engineered or selected to prevent, treat, or cure disease. Investors should care because these products combine biological activity with complex manufacturing and strict safety testing, so their value depends heavily on clinical trial results, regulatory approval, and the ability to produce and store living cultures reliably, like investing in a factory that must keep its product alive to work.

nasdaq listing rule 5635(c)(4) regulatory

"pursuant to Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4, 2026, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 4,200 shares of its common stock to two new employees. These stock options are subject to the terms of the Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan (the “Inducement Plan”). The Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to their entering into employment with Seres pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan was adopted by Seres’ board of directors in December 2022. The stock options have an exercise price of $5.72 per share. Each option will vest as to 25% of the total number of shares subject to the option on the first anniversary of the individual’s date of hire and as to 6.25% of the total number of shares subject to the option upon completion of each three full months of service to the Company thereafter.

About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics products, designed to address unmet needs in oncology that can lead to interruption to patients' cancer care and/or mortality, and to treat inflammatory and immune diseases, by modulating host function to protect and improve mucosal epithelial barrier integrity, induce immune homeostasis and tolerance, and prevent the colonization and overgrowth of pathogens in the gastrointestinal tract. For more information, please visit www.serestherapeutics.com.

Investor and Media Contact:
IR@serestherapeutics.com